Cargando…

Design of a stabilized non-glycosylated Pfs48/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine

A malaria vaccine that blocks parasite transmission from human to mosquito would be a powerful method of disrupting the parasite lifecycle and reducing the incidence of disease in humans. Pfs48/45 is a promising antigen in development as a transmission blocking vaccine (TBV) against the deadliest ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dickey, Thayne H., Gupta, Richi, McAleese, Holly, Ouahes, Tarik, Orr-Gonzalez, Sachy, Ma, Rui, Muratova, Olga, Salinas, Nichole D., Hume, Jen C. C., Lambert, Lynn E., Duffy, Patrick E., Tolia, Niraj H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9938515/ https://www.ncbi.nlm.nih.gov/pubmed/36808125 http://dx.doi.org/10.1038/s41541-023-00619-9

Ejemplares similares

A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle
por: Salinas, Nichole D., et al.
Publicado: (2023)

Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response
por: Dickey, Thayne H., et al.
Publicado: (2022)

Structure-based design of a strain transcending AMA1-RON2L malaria vaccine
por: Patel, Palak N., et al.
Publicado: (2023)

Design of a stabilized RBD enables potently neutralizing SARS-CoV-2 single-component nanoparticle vaccines
por: Dickey, Thayne H., et al.
Publicado: (2023)

Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48/45 proteins
por: Singh, Kavita, et al.
Publicado: (2020)

Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine
por: Singh, Susheel K., et al.
Publicado: (2021)

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum
por: Singh, Susheel K., et al.
Publicado: (2019)

Rare Alleles and Signatures of Selection on the Immunodominant Domains of Pfs230 and Pfs48/45 in Malaria Parasites From Western Kenya
por: Ochwedo, Kevin O., et al.
Publicado: (2022)

Preclinical evaluations of Pfs25-EPA and Pfs230D1-EPA in AS01 for a vaccine to reduce malaria transmission
por: Rausch, Kelly M., et al.
Publicado: (2023)

Critical Glycosylated Residues in Exon Three of Erythrocyte Glycophorin A Engage Plasmodium falciparum EBA-175 and Define Receptor Specificity
por: Salinas, Nichole D., et al.
Publicado: (2014)

Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45
por: Kundu, Prasun, et al.
Publicado: (2018)

Structure of the malaria vaccine candidate Pfs48/45 and its recognition by transmission blocking antibodies
por: Ko, Kuang-Ting, et al.
Publicado: (2022)

The Dynamics of Naturally Acquired Immune Responses to Plasmodium falciparum Sexual Stage Antigens Pfs230 & Pfs48/45 in a Low Endemic Area in Tanzania
por: Bousema, Teun, et al.
Publicado: (2010)

Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody
por: Lennartz, Frank, et al.
Publicado: (2018)

A human antibody epitope map of the malaria vaccine antigen Pfs25
por: Shukla, Niharika, et al.
Publicado: (2023)

Structural analysis of Plasmodium falciparum ookinete surface antigen Pfs28 relevant for malaria vaccine design
por: Shukla, Niharika, et al.
Publicado: (2022)

Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana
por: Acquah, Festus K., et al.
Publicado: (2017)

Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice
por: Healy, Sara A., et al.
Publicado: (2021)

Structural and immunological differences in Plasmodium falciparum sexual stage transmission-blocking vaccines comprised of Pfs25-EPA nanoparticles
por: MacDonald, Nicholas J., et al.
Publicado: (2023)

Profiling the Quality and Quantity of Naturally Induced Antibody Responses Against Pfs230 and Pfs48/45 Among Non-Febrile Children Living in Southern Ghana: A Longitudinal Study
por: Broni, Fermin K., et al.
Publicado: (2021)

A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system
por: Lee, Shwu-Maan, et al.
Publicado: (2020)

A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine
por: Singh, Susheel K., et al.
Publicado: (2021)

Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes
por: Fabra-García, Amanda, et al.
Publicado: (2023)

A Potent Malaria Transmission Blocking Vaccine Based on Codon Harmonized Full Length Pfs48/45 Expressed in Escherichia coli
por: Chowdhury, Debabani Roy, et al.
Publicado: (2009)

A Plant-Produced in vivo deglycosylated full-length Pfs48/45 as a Transmission-Blocking Vaccine Candidate against malaria
por: Mamedov, Tarlan, et al.
Publicado: (2019)

Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses
por: McLeod, Brandon, et al.
Publicado: (2022)

Outer membrane protein complex as a carrier for malaria transmission blocking antigen Pfs230
por: Scaria, Puthupparampil V., et al.
Publicado: (2019)

Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines
por: Scaria, Puthupparampil V., et al.
Publicado: (2022)

Plant-produced transmission blocking Plasmodium falciparum Pfs25 subunit and VLP based vaccine candidates
por: Musivchuk, Konstantin, et al.
Publicado: (2012)

Comparison of Intranasal Outer Membrane Vesicles with Cholera Toxin and Injected MF59C.1 as Adjuvants for Malaria Transmission Blocking Antigens AnAPN1 and Pfs48/45
por: Pritsch, Michael, et al.
Publicado: (2016)

Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer
por: Miura, Kazutoyo, et al.
Publicado: (2007)

Neutralizing and interfering human antibodies define the structural and mechanistic basis for antigenic diversion
por: Patel, Palak N., et al.
Publicado: (2022)

Structural and Functional Basis for Inhibition of Erythrocyte Invasion by Antibodies that Target Plasmodium falciparum EBA-175
por: Chen, Edwin, et al.
Publicado: (2013)

Structural Analysis of the Synthetic Duffy Binding Protein (DBP) Antigen DEKnull Relevant for Plasmodium vivax Malaria Vaccine Design
por: Chen, Edwin, et al.
Publicado: (2015)

No evidence of increased susceptibility to COVID-19 virus among radical lung radiotherapy patients
por: Lepiarczyk, Oskar, et al.
Publicado: (2021)

Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel® in mice
por: Coelho, Camila H., et al.
Publicado: (2019)

Chloroquine neither eliminates liver stage parasites nor delays their development in a murine Chemoprophylaxis Vaccination model
por: Sahu, Tejram, et al.
Publicado: (2015)

Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose
por: Huang, Wei-Chiao, et al.
Publicado: (2020)

Phase 1 Trial of Malaria Transmission Blocking Vaccine Candidates Pfs25 and Pvs25 Formulated with Montanide ISA 51
por: Wu, Yimin, et al.
Publicado: (2008)

Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas
por: Baptista, Barbara Oliveira, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1gltp2c20d53h2eeaqf7oule9h